These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 27241838)
1. Independent Link Between Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and FABP4 in a General Population Without Medication. Furuhashi M; Omori A; Matsumoto M; Kataoka Y; Tanaka M; Moniwa N; Ohnishi H; Yoshida H; Saitoh S; Shimamoto K; Miura T Am J Cardiol; 2016 Jul; 118(2):198-203. PubMed ID: 27241838 [TBL] [Abstract][Full Text] [Related]
2. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population. Hamamura H; Adachi H; Enomoto M; Fukami A; Nakamura S; Nohara Y; Morikawa N; Sakaue A; Toyomasu K; Yamamoto M; Fukumoto Y J Atheroscler Thromb; 2021 Apr; 28(4):329-337. PubMed ID: 32624555 [TBL] [Abstract][Full Text] [Related]
3. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox". Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349 [TBL] [Abstract][Full Text] [Related]
4. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy. Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939 [TBL] [Abstract][Full Text] [Related]
5. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control. Bojanin D; Vekic J; Milenkovic T; Vukovic R; Zeljkovic A; Stefanovic A; Janac J; Ivanisevic J; Mitrovic K; Miljkovic M; Spasojevic-Kalimanovska V Atherosclerosis; 2019 Jan; 280():14-20. PubMed ID: 30453116 [TBL] [Abstract][Full Text] [Related]
6. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis]. Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908 [TBL] [Abstract][Full Text] [Related]
7. Roux-en-Y gastric bypass, but not sleeve gastrectomy, decreases plasma PCSK9 levels in morbidly obese patients. Blanchard C; Ledoux S; Verhaegen A; Wargny M; Letessier E; Stepanian A; Huten N; Jacobi D; Krempf M; Le Bras M; Perrocheau Guillouche M; Arnaud L; Pichelin M; Van Gaal L; Cariou B; Le May C Diabetes Metab; 2020 Nov; 46(6):480-487. PubMed ID: 32032671 [TBL] [Abstract][Full Text] [Related]
8. Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C. Li S; Zhao X; Zhang Y; Zhu CG; Guo YL; Wu NQ; Xu RX; Qing P; Gao Y; Sun J; Liu G; Dong Q; Li JJ Oncotarget; 2017 Feb; 8(7):12333-12341. PubMed ID: 27713142 [TBL] [Abstract][Full Text] [Related]
9. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects. Kwakernaak AJ; Lambert G; Muller Kobold AC; Dullaart RP Thyroid; 2013 Feb; 23(2):166-72. PubMed ID: 23106476 [TBL] [Abstract][Full Text] [Related]
10. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Werner C; Hoffmann MM; Winkler K; Böhm M; Laufs U Vascul Pharmacol; 2014 Aug; 62(2):94-102. PubMed ID: 24685817 [TBL] [Abstract][Full Text] [Related]
11. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study. Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351 [TBL] [Abstract][Full Text] [Related]
12. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy. Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S Cardiovasc Diabetol; 2020 Jun; 19(1):89. PubMed ID: 32539832 [TBL] [Abstract][Full Text] [Related]
13. Increased serum PCSK9, a potential biomarker to screen for periodontitis, and decreased total bilirubin associated with probing depth in a Japanese community survey. Tabeta K; Hosojima M; Nakajima M; Miyauchi S; Miyazawa H; Takahashi N; Matsuda Y; Sugita N; Komatsu Y; Sato K; Ishikawa T; Akiishi K; Yamazaki K; Kato K; Saito A; Yoshie H J Periodontal Res; 2018 Jun; 53(3):446-456. PubMed ID: 29516504 [TBL] [Abstract][Full Text] [Related]
14. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841 [TBL] [Abstract][Full Text] [Related]
15. Circulating PCSK7 Level is Independently Associated with Obesity, Triglycerides Level and Fatty Liver Index in a General Population without Medication. Furuhashi M; Kataoka Y; Nishikawa R; Koyama M; Sakai A; Higashiura Y; Tanaka M; Saitoh S; Shimamoto K; Ohnishi H J Atheroscler Thromb; 2022 Sep; 29(9):1275-1284. PubMed ID: 34565765 [TBL] [Abstract][Full Text] [Related]
16. Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals. Tanaka M; Takahashi S; Higashiura Y; Sakai A; Koyama M; Saitoh S; Shimamoto K; Ohnishi H; Furuhashi M J Diabetes Investig; 2022 May; 13(5):878-888. PubMed ID: 34889064 [TBL] [Abstract][Full Text] [Related]
17. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study. Simonen P; Stenman UH; Gylling H Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271 [TBL] [Abstract][Full Text] [Related]
18. Metabolic Changes Induced by Bariatric Surgery May be Mediated by PAI-1 and PCSK9 Crosstalk. Castro-Leyva V; Manuel-Apolinar L; Basurto-Acevedo NE; Basurto L; González-Chávez A; Ruiz-Gastelum E; Martínez-Murillo C Arch Med Res; 2024 Jul; 55(5):103032. PubMed ID: 38971127 [TBL] [Abstract][Full Text] [Related]
19. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk. Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668 [TBL] [Abstract][Full Text] [Related]
20. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9. Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]